scholarly article | Q13442814 |
P356 | DOI | 10.1177/1078155211411001 |
P698 | PubMed publication ID | 21807763 |
P50 | author | Saif S Ahmad | Q55426428 |
P2093 | author name string | M Lewis | |
P Corrie | |||
M Iddawela | |||
P2860 | cites work | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
International consensus report on the investigation and management of primary immune thrombocytopenia | Q28262094 | ||
A method for estimating the probability of adverse drug reactions | Q29616247 | ||
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? | Q33205393 | ||
Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management | Q33384003 | ||
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer | Q33389767 | ||
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival | Q34048270 | ||
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review | Q36846876 | ||
Current systemic therapy for metastatic melanoma | Q37483961 | ||
Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab | Q37809151 | ||
Current management of metastatic melanoma | Q46217401 | ||
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). | Q51800094 | ||
P433 | issue | 2 | |
P921 | main subject | ipilimumab | Q2459042 |
patient | Q181600 | ||
thrombocytopenia | Q585285 | ||
metastatic melanoma | Q18975855 | ||
P304 | page(s) | 287-292 | |
P577 | publication date | 2011-08-01 | |
P1433 | published in | Journal of Oncology Pharmacy Practice | Q6295681 |
P1476 | title | Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma | |
P478 | volume | 18 |
Q26858779 | Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application |
Q52641422 | Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. |
Q33434066 | Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report |
Q89526156 | Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events |
Q37629874 | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy |
Q90639031 | Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management |
Q64085283 | Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia |
Q26785746 | Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis |
Q36841621 | Immunomodulatory therapy for melanoma: ipilimumab and beyond |
Q36292634 | Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. |
Q33777476 | Ipilimumab and its toxicities: a multidisciplinary approach |
Q38171355 | Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells |
Q31034415 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper |
Q87997894 | Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update |
Q47164715 | Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events |
Q89947448 | Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review |
Q27008140 | Toxicities of Immunotherapy for the Practitioner |
Search more.